• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BD wins Frost & Sullivan innovation award for Intevia autoinjector

February 16, 2021 By Sean Whooley

Frost & Sullivan announced today that it recognizes Becton Dickinson (NYSE:BDX) with a 2020 Global Technology Innovation Award.

BD received the award for its Intevia autoinjector, which, as part of the company’s differentiated self-injection systems portfolio, facilitates high-viscosity biologics delivery for treating chronic diseases, according to a news release.

Intevia, a two-step, push-on-skin, handheld autoinjector delivers biologic medicines of differing viscosities and can be adapted to deliver a range of drug volumes without any need to customize the system and subsystem components.

Becton Dickinson launched the BD Intevia 1mL platform in 2019 and is currently developing a 2.25mL version as a patient-centric device to be integrated with the BD Neopak XtraFlow prefillable syringes.

The award from Frost & Sullivan for the Intevia technology recognizes a product with innovative features and functionality that is gaining rapid acceptance in the market, according to the consulting firm.

“BD Intevia’s 1-mL and 2.25-mL dose configurations meet the demand for a delivery mechanism for viscous biologics. The drug-device combination improves the self-injection experience in home settings, which, in turn, improves disease management, patient adherence, and quality of life,” Frost & Sullivan industry principal Unmesh Lal said in the release. “BD Intevia’s 1 mL design configuration integrates the control point feature that allows the autoinjector to probe the target site without getting activated, allowing patients to test the target injection site and choose the location.”

“A partner in the customer assembly and filling process, BD assists pharma customers in installing facilities for filing and assembly equipment at their production site or contract manufacturing organization. Maintaining a global footprint with manufacturing, commercial, and technical organizations across multiple geographies, BD’s breadth of capabilities cements its position as a global leader in self-injection systems.”

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Becton Dickinson, Frost & Sullivan

IN CASE YOU MISSED IT

  • Lyra Therapeutics appoints new chief medical officer
  • FDA lifts hold on Vertex’s insulin-producing cell therapy for diabetes
  • Retractable Technologies declares dividends
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • West Pharmaceutical Services debuts new needle syringe system

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS